Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

[...]we should evaluate the efficacy of therapeutic drugs and the effect of COVID-19 vaccines against XBB.1.5. [...]we evaluated the antiviral drugs remdesivir (an RNA-dependent RNA polymerase [RDRP] inhibitor), which is approved for the treatment of COVID-19 by the US Food and Drug Administration (...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2023-04, Vol.23 (4), p.402-403
Main Authors: Uraki, Ryuta, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Furusawa, Yuri, Sakai-Tagawa, Yuko, Imai, Masaki, Koga, Michiko, Yamamoto, Shinya, Adachi, Eisuke, Saito, Makoto, Tsutsumi, Takeya, Otani, Amato, Kikuchi, Tetsuhiro, Yotsuyanagi, Hiroshi, Halfmann, Peter J, Pekosz, Andrew, Kawaoka, Yoshihiro
Format: Article
Language:English
Subjects:
Amino acids
Antiviral agents
Antiviral Agents - therapeutic use
Clinical trials
Coronaviruses
Correspondence
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Disease transmission
DNA-directed RNA polymerase
Drug development
Drug dosages
Drugs
Effectiveness
Humans
Infections
Infectious diseases
Medical research
Monoclonal antibodies
mRNA vaccines
Pharmaceuticals
Plasma
Protease
Protease inhibitors
Proteinase inhibitors
R&D
Regulatory approval
Research & development
RNA polymerase
RNA-directed RNA polymerase
Severe acute respiratory syndrome coronavirus 2
Vaccine efficacy
Vaccines
Vaccines, Combined
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]we should evaluate the efficacy of therapeutic drugs and the effect of COVID-19 vaccines against XBB.1.5. [...]we evaluated the antiviral drugs remdesivir (an RNA-dependent RNA polymerase [RDRP] inhibitor), which is approved for the treatment of COVID-19 by the US Food and Drug Administration (FDA); molnupiravir (also an RDRP inhibitor) and nirmatrelvir (a main protease inhibitor), both of which are authorised for emergency use by the US FDA; and ensitrelvir (a main protease inhibitor), which has emergency regulatory approval in Japan and is currently in phase 3 clinical trials in the USA. [...]we tested the neutralising ability of plasma from people who were convalescent and people who had had the COVID-19 vaccine against XBB.1.5.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00070-1